Immunome's Chief Medical Officer Sells Shares

On June 25, 2026, Robert Lechleider, the Chief Medical Officer of Immunome, Inc. (NasdaqCM: IMNM), sold 55,000 shares of the company. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Immunome, Inc.

Robert Lechleider's recent sale of 55,000 shares was recorded on June 25, 2026. Earlier on the same day, he also acquired 55,000 shares at an average price of $8.73. Additionally, Max Rosett, the Chief Financial Officer, sold 60,000 shares on June 15, 2026, with an average price of $18.23, while also making a non-planned purchase of 60,000 shares at $1.05 on the same day.

Other Institutional Activity in Immunome

Several institutional investors have adjusted their positions in Immunome. FMR LLC increased its holdings by 420,238 shares, bringing its total to 16,969,954 shares valued at approximately $371.1 million, a 2.5% increase. T. Rowe Price Investment Management, Inc. added 2,942,024 shares, ending with 16,364,011 shares valued at $357.9 million, reflecting a 21.9% increase. BlackRock, Inc. also grew its position by 573,678 shares, holding 8,168,674 shares worth about $178.6 million, marking a 7.6% rise. On the other hand, Redmile Group, LLC reduced its stake by 159,500 shares to 5,558,885 shares, valued at $121.6 million, a 2.8% decrease. State Street Corp significantly increased its position by 1,531,901 shares, now holding 5,399,901 shares worth $118.1 million, a 39.6% increase.

Immunome, Inc. Stock Down 23.7%

Shares of Immunome, Inc. traded near $19.96 on Tuesday. The company has a market cap of approximately $2.26 billion and a beta of 2.07, indicating higher volatility than the broader market. Over the past year, the stock has ranged from a low of $7.96 to a high of $27.65. Its 50-day moving average is $21.25, and the 200-day moving average is $19.58.

Analysts Set New Price Targets

Analyst firms have shown positive sentiment towards Immunome. On June 12, 2026, Wedbush reiterated its 'buy' rating with a $31.00 price target. Earlier, on May 28, Truist Securities maintained a 'buy' rating with a $37.00 target, and Barclays initiated coverage with a 'buy' rating and a $36.00 target. The consensus target price is around $35.77 from 13 analysts.

About Immunome, Inc.

Immunome, Inc. is a biotechnology company based in Bothell, Washington. It focuses on developing antibody-drug conjugates and other oncology therapeutics. Among its key projects are Varegacestat, in Phase 3 trials for desmoid tumors, and IM-1021, in Phase 1 trials. The company, led by CEO Dr. Clay B. Siegall, employs about 206 people.

Bottom Line

Robert Lechleider's recent share sale is part of ongoing insider activity at Immunome. The company's stock remains a point of interest for institutional investors and analysts, reflecting varied positions and positive analyst ratings. As always, insider trades are disclosed after the fact and should be considered in the broader context of ongoing market dynamics.